Embolx Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • Series C
  • Investors
  • 14

Embolx General Information

Description

Developer of balloon occlusion microcatheters designed to treat cancerous tumors, benign prostatic hyperplasia, and uterine fibroids. The company's microcatheters set a new standard for precise embolic delivery and superior target filling by controlling pressure to direct blood flow while protecting non-target surrounding tissues, thereby enabling doctors to improve treatment for a variety of conditions and kill the tumor.

Contact Information

Website
www.embolx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Surgical Devices
Primary Office
  • 530 Lakeside Drive
  • Suite 200
  • Sunnyvale, CA 94085
  • United States
+1 (408) 000-0000

Embolx Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Embolx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series C) 01-Jul-2021 000.00 Completed Generating Revenue
9. Debt - PPP 13-Apr-2020 000.00 Completed Generating Revenue
8. Later Stage VC 29-Jan-2019 00.00 000.00 Completed Generating Revenue
7. Later Stage VC 00.00 Completed Generating Revenue
6. Grant 06-Apr-2018 000 00.00 Completed Generating Revenue
5. Early Stage VC (Series B) 01-Nov-2017 00.00 00.00 000.00 Completed Generating Revenue
4. Early Stage VC (Series A2) 15-Jun-2016 00.000 00.000 000.00 Completed Generating Revenue
3. Grant 01-Jan-2015 00000 00.000 Completed Generating Revenue
2. Early Stage VC (Series A1) 30-Nov-2014 $1.5M $1.75M 000 Completed Generating Revenue
1. Early Stage VC (Series A) 09-May-2014 $250K $250K 000000 Completed Generating Revenue
To view Embolx’s complete valuation and funding history, request access »

Embolx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000 00 000.00 000.00 00 000.00 00.000
Series A2 000,000 00 000.00 000.00 00 000.00 00.000
Series A1 404,836 8% $3.74 $3.74 1x $3.74 17.61%
Series A 151,874 8% $3.29 $3.29 1x $3.29 6.61%
To view Embolx’s complete cap table history, request access »

Embolx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of balloon occlusion microcatheters designed to treat cancerous tumors, benign prostatic hyperplasia, and uter
Surgical Devices
Sunnyvale, CA
13 As of 2021
000.00
00000000000 000.00

00000000

olor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
00000000 0000000
Westminster, CO
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Embolx Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000000 0000 0000 Venture Capital-Backed Westminster, CO 00 000.00 00000000000 000.00
You’re viewing 1 of 1 competitors. Get the full list »

Embolx Patents

Embolx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200030577-A1 Shaped catheter tip for tracking over a guidewire through turns in the vasculature Pending 27-Jul-2018 00000000000
EP-3829688-A1 Shaped catheter tip for tracking over a guidewire through turns in the vasculature Pending 27-Jul-2018 00000000000
US-20200023170-A1 Balloon catheters and methods of manufacture and use Pending 16-Feb-2016 00000000000 0
US-10667822-B2 Devices and methods for low pressure tumor embolization Active 08-May-2013 000000000000
US-20180125502-A1 Devices and methods for low pressure tumor embolization Granted 08-May-2013 A61B17/12186 0
To view Embolx’s complete patent history, request access »

Embolx Executive Team (6)

Name Title Board Seat Contact Info
Michael Allen Chief Executive Officer, President & Board Member
Michael Lin Director of Finance
Ben Felipe Director of Sales
You’re viewing 3 of 6 executive team members. Get the full list »

Embolx Board Members (6)

Name Representing Role Since
Frank Grillo Self Board Member & Secretary 000 0000
Michael Allen Embolx Chief Executive Officer, President & Board Member 000 0000
Norman Gitis Ph.D Band of Angels Chairman 000 0000
Paul Rogan Self Board Member 000 0000
Robert de Neve Embolx Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Embolx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Embolx Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
Acorn Campus Taiwan Venture Capital Minority 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
VI Ventures Venture Capital Minority 000 0000 000000 0
Acorn Campus Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »